EUEuropean Union
Kyinsu indication in the EU set to widen as the label waits on a Commission decision
The EMA committee backed dropping the need to try basal insulin or a GLP-1 drug before Kyinsu, the weekly insulin icodec and semaglutide pen. A first revision of its EU file appeared on 16 November, but the label still shows the old wording.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itThe EMA committee recommended widening the EU indication of Kyinsu, the weekly insulin icodec and semaglutide pen, and the agency posted a first EPAR revision on 16 November while the label still shows the original wording.
The Kyinsu indication in the European Union is set to widen, but the change has not yet reached the product label. Kyinsu, Novo Nordisk's once weekly injection that joins the basal insulin icodec with semaglutide, was authorised across the EU on 24 November 2025 for adults whose type 2 diabetes was not controlled on basal insulin or on a GLP-1 drug. In October the EMA's medicines committee recommended dropping that requirement. On 16 November the agency logged a first revision of the Kyinsu EPAR file and new product information, while the label it published still carries the original indication.
What the committee recommended in October
The Committee for Medicinal Products for Human Use adopted a positive opinion on 15 October 2026 to change the existing indication, according to the EMA opinion on the variation. In the text it published, the words limiting use to patients insufficiently controlled on basal insulin or GLP-1 receptor agonists are struck out. The new wording would cover adults with insufficiently controlled type 2 diabetes, still as an add on to diet and exercise and to diabetes medicines taken by mouth. In plain terms, a doctor would no longer need to have tried a basal insulin or a GLP-1 drug first before moving a patient onto the combination. The October meeting highlights listed Kyinsu among five medicines that received extensions of indication that month.
The committee's opinion is a recommendation. The European Commission takes the legally binding decision, and the EMA said the updated summary of product characteristics would appear in all EU languages once the Commission had decided. The EMA opinion page did not publish the clinical data behind the wider wording, and the agency's short note does not say which study supports use in people who have not tried either drug class. The opinion page names Novo Nordisk A/S as the holder but carries no comment from the company. Until the Commission acts and the label is updated, the authorised Kyinsu indication remains the narrower one granted a year ago, and prescribers in member states work from that text.
What changed on 16 November
The EMA page for Kyinsu now shows revision 1, and its product information was marked as updated on 16 November under procedure VR/0000380695. A new document, the procedural steps taken after authorisation, was published the same day. The page does not say what the procedure covered. When Peptide Global read the product information file on 19 November, section 4.1 still described adults with type 2 diabetes insufficiently controlled on basal insulin or GLP-1 receptor agonists. So the November update did not, at least by that date, carry the wider October wording, and readers should not treat the revision as the Commission decision on the new indication.
So the November update did not, at least by that date, carry the wider October wording, and readers should not treat the revision as the Commission decision on the new indication.
The distinction matters because European labels drive national decisions. Health technology bodies and payers in each member state judge a medicine against its authorised indication, so a wider label can open talks on reimbursement for a larger group of patients. Kyinsu is also under additional monitoring in the EU, shown by a black triangle, which means suspected side effects are watched more closely than for older medicines. The EMA overview says the company must give every patient an educational guide to reduce medication errors, including mix ups with other injectable diabetes treatments when people switch to a once weekly product. Those duties stay in place whatever the outcome of the indication change.
The Kyinsu indication and the COMBINE studies
The original approval rested on three Phase 3a trials called COMBINE, each running 52 weeks and together enrolling 2,653 people, according to the EMA assessment report on the EMA site. All three were open label. COMBINE 1 randomised 1,291 adults on daily basal insulin to Kyinsu or to insulin icodec alone. COMBINE 2 took 683 adults who had never used insulin but were not controlled on a GLP-1 drug and compared Kyinsu with semaglutide alone. COMBINE 3 put 679 adults on basal insulin onto Kyinsu or a regimen of daily insulin glargine plus mealtime insulin aspart. The main measure in each trial was HbA1c, a marker of average blood sugar.
| Item | Detail |
|---|---|
| Medicine | Kyinsu, insulin icodec and semaglutide, once weekly prefilled pen |
| Holder | Novo Nordisk A/S, Bagsvaerd, Denmark |
| EU authorisation | 24 November 2025 |
| Pivotal trials | COMBINE 1, 2 and 3, 52 weeks each, 2,653 patients in total |
| Committee opinion on wider indication | 15 October 2026 |
| EPAR revision 1 and product information update | 16 November 2026 |
| Indication in label as of 19 November | Adults insufficiently controlled on basal insulin or GLP-1 receptor agonists |
| Commission decision on the wider indication | Not yet shown on the EMA page |
The EMA summary says Kyinsu improved blood sugar control in all three groups. In people coming from insulin it also brought weight loss, while in people coming from a GLP-1 drug it was linked to weight gain, unlike the loss usually seen with GLP-1 drugs alone. The most common side effects, affecting more than one in ten people, were low blood sugar and stomach and gut problems such as nausea and diarrhoea. The agency judged the benefits greater than the risks and noted that having both medicines in one injection may help people keep to treatment. None of the three trials enrolled people new to both insulin and GLP-1 drugs, which is the group a wider indication would most clearly add.
What to watch next
The first item is the Commission decision and the updated summary of product characteristics. When it appears, section 4.1 will show the final wording and section 5.1 may describe any new study data that supported it. The second is national uptake. A weekly product that combines a basal insulin and a GLP-1 drug could change how doctors start injectable treatment, but reimbursement is decided country by country and no national decision has been announced. The third is safety reporting. With wider use, the black triangle monitoring and the educational guide on dosing errors become more important, because patients switching from daily insulin to a weekly product face a new routine.
Kyinsu also sits in a busier European market for peptide medicines. The EU authorised Zeydovio for short bowel syndrome on 12 November, a reminder that the agency is handling several gut hormone products at once. Insulin supply in Europe is being expanded as well. Sanofi has started work on a new Frankfurt insulin plant with supply duties running for years. Semaglutide protection is falling away in several markets outside Europe, as our semaglutide patent map shows, but Kyinsu is a branded combination that pairs the molecule with a newer insulin. Novo Nordisk has not given launch dates or prices for Kyinsu by country, and none are assumed here.
Conclusion
The EMA's medicines committee backed a wider Kyinsu indication in October that would drop the need to try basal insulin or a GLP-1 drug first. A first revision of the Kyinsu file appeared on 16 November, but the label it published still carried the original wording on 19 November. The Commission decision and the updated product information are the next documents to watch, followed by national reimbursement choices.
Why it matters in European Union
A wider EU label would let doctors start Kyinsu without first trying basal insulin or a GLP-1 drug, and national payers judge reimbursement against the authorised indication, so the final wording shapes access across member states.
What to watch
The Commission decision and the updated summary of product characteristics, the study data cited for the wider use, and national reimbursement decisions.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.